atropine has been researched along with Disease Exacerbation in 161 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (2.48) | 18.2507 |
| 2000's | 19 (11.80) | 29.6817 |
| 2010's | 51 (31.68) | 24.3611 |
| 2020's | 87 (54.04) | 2.80 |
| Authors | Studies |
|---|---|
| Chuang, MN; Fang, PC; Wu, PC | 1 |
| Barrio-Barrio, J; Macías-Murelaga, B; Pérez-Flores, I | 2 |
| Diaz-Valle, D; Gomez-de-Liaño, R; Morales-Fernández, L; Moriche-Carretero, M; Revilla-Amores, R | 1 |
| Darband, SG; Ghaderi-Pakdel, F; Majidinia, M; Mihanfar, A; Sadighparvar, S | 1 |
| Boland, B; Lipson, MJ; McAlinden, C | 1 |
| Jethani, J | 1 |
| Jan, CL; Morgan, IG | 1 |
| Venkatesh, P | 1 |
| Cyphers, B; Huang, J; Walline, JJ | 1 |
| Rhee, MK | 1 |
| Frick, KD; Fricke, TR; He, M; Naduvilath, T; Resnikoff, S; Sankaridurg, P; Tahhan, N | 1 |
| Agho, KE; Berntsen, DA; Ekpenyong, BN; Ekure, E; Kyei, S; Mashige, KP; Naidoo, KS; Ndep, AO; Nti, AN; Obinwanne, CJ; Ocansey, S; Ogbuehi, KC; Osuagwu, UL; Ouzzani, M; Ovenseri-Ogbomo, G; Owusu-Afriyie, B; Wolffsohn, JS | 1 |
| Jones, JH; Jones-Jordan, LA; Mutti, DO; Walline, JJ | 1 |
| Chen, PL; Chen, YH; Chien, KH; Hsieh, MW; Lee, LC | 1 |
| Kurihara, T; Negishi, K; Shinojima, A; Tsubota, K | 1 |
| Chan, HHL; Chan, JCH; Chan, SSH; Choi, KY; Choy, BNK; Li, SZC; Ng, ALK; Yu, WY | 1 |
| Dhiman, R; Gupta, V; Rakheja, V; Saxena, R | 1 |
| An, W; Bai, W; Cai, Z; Du, J; Gan, J; Li, SM; Liang, X; Sun, Y; Tian, J; Wang, N; Wei, S; Yin, L | 1 |
| Gupta, P; Jain, A; Sen, S; Verma, S; Yadav, H | 1 |
| Azuara-Blanco, A; Blaszkowska, M; Chia, A; Clark, A; Crewe, JM; Flitcroft, DI; Franchina, M; Hammond, CJ; Koay, A; Lee, SS; Lingham, G; Loughman, J; Mackey, DA; Sanfilippo, PG | 1 |
| Bullimore, MA; Novack, GD; Richdale, K; Tomiyama, ES | 1 |
| Hasebe, S; Sun, W | 1 |
| Wabbels, B | 1 |
| Aller, T; Chan, K; Cooper, J; Dillehay, SM; O'Connor, B; Smith, EL | 1 |
| Chen, XF; Du, CX; He, T; Huang, Z; Tang, Y | 1 |
| Bhatia, R; Chhabra, P; Das, GK; Rohatgi, J; Sahu, PK; Sharma, I | 1 |
| Grzybowski, A; Lanca, C; Repka, MX | 1 |
| Bui, CHT; Chen, LJ; Kam, KW; Ko, ST; Ng, MPH; Pang, CP; Tang, F; Tham, CC; Wong, ES; Yam, JC; Yip, BHK; Yip, WWK; Young, AL; Zhang, XJ; Zhang, Y | 1 |
| Edgar, DF; Evans, BJW; Lembo, A; Nucci, P; Schiavetti, I; Shah, R | 1 |
| Brennan, NA; Bullimore, MA | 1 |
| Hiraoka, R; Hiraoka, T; Kiuchi, G; Maruo, K; Oshika, T | 1 |
| Chen, LJ; Kam, KW; Pang, CP; Tham, CC; Yam, JC; Zhang, XJ | 1 |
| De Zeeuw, CI; Hamelink, R; Klaver, CCW; Meester-Smoor, MA; Polling, JR; Tan, E; Thiadens, AAHJ; Tideman, JWL; van der Sande, E; Verhoeven, VJM; Willuhn, I; Winkelman, BHJ | 1 |
| Wang, Y; Xia, L; Zhao, H | 1 |
| Fu, A; Huang, C; Ma, N; Wang, M; Wang, W; Wei, L; Yu, S; Zhang, F; Zhang, J | 1 |
| Ha, A; Jung, JH; Kim, SJ; Kim, YK | 1 |
| Olshaker, H; Shemesh, N | 1 |
| Jiang, J; Qu, C; Zhang, G | 1 |
| Berntsen, DA; Bullimore, MA; Cho, P; Flitcroft, I; Gawne, TJ; Gifford, KL; Jong, M; Kang, P; Ostrin, LA; Sankaridurg, P; Santodomingo-Rubido, J; Wildsoet, C; Wolffsohn, JS | 1 |
| Dahlmann-Noor, A | 1 |
| Liu, SH; Nucci, P; Villani, E | 1 |
| Li, X; Long, H; Shi, MH | 1 |
| Eppenberger, LS; Sturm, V | 1 |
| Agarkar, S; Chowdhury, S; Gopalakrishnan, A; Hussain, A | 1 |
| Yam, JC; Zhang, XJ; Zhang, Y | 1 |
| Kataoka, Y; Someko, H; Tsuda, H | 1 |
| Barros da Silva, P; Guimarães, S; Oliveiros, B; Silva, E | 1 |
| Beck, RW; Chandler, DL; Cotter, SA; Erzurum, SA; Holmes, JM; Jordan, CO; Kehler, LAF; Kraker, RT; Lee, KA; Lenhart, PD; Manny, RE; Melia, BM; Pang, Y; Petersen, DB; Raghuram, A; Repka, MX; Summers, AI; Ticho, BH; Weise, KK; Wu, R | 1 |
| Berntsen, DA; Walline, JJ | 1 |
| Bu, F; Sun, H; Xin, X; Yan, J | 1 |
| Fujikado, T; Hasebe, S; Hieda, O; Hiraoka, T; Ishiko, S; Kinoshita, S; Takahashi, H; Tanaka, S; Torii, H | 1 |
| Jiang, Z; Peng, W; Wang, F | 1 |
| Callisto, S; Chan, WO; Taranath, D; Usmani, E | 1 |
| Teper, S; Wnękowicz-Augustyn, E; Wylęgała, E | 1 |
| Bek, T; Hansen, NC; Hvid-Hansen, A; Jacobsen, N; Kessel, L; Larsen, DA; Møller, F | 1 |
| Farzavandi, SK; Gomez-de-Liaño, R; Leshno, A; Mezer, E; Sprunger, DT; Wygnanski-Jaffe, T | 1 |
| Ma, JX; Zhao, F | 1 |
| Khanal, S; Phillips, JR | 1 |
| Fan, L; Gu, H; Guo, L; Hua, R; Li, L; Tao, J; Yang, Q; Yu, S; Zhao, X | 1 |
| Beuerman, RW; Upadhyay, A | 1 |
| Chen, LJ; Kam, KW; Ko, ST; Li, FF; Pang, CP; Tang, SM; Tham, CC; Yam, JC; Yip, BHK; Young, AL; Zhang, X | 1 |
| Guo, L; Hu, M; Tang, Y; Tighe, S; Zhang, J; Zhang, X; Zhou, Y; Zhu, Q; Zhu, Y | 1 |
| Fu, A; Ji, N; Lyu, Y; Stapleton, F; Wang, W; Watt, K; Wei, L; Zhao, B | 1 |
| Azuara-Blanco, A; Charng, J; Chen, FK; Chia, A; Clark, A; Crewe, JM; Flitcroft, I; Hammond, CJ; Lee, SSY; Lingham, G; Logan, NS; Loughman, JJ; Mackey, DA; Ng, F; Richards, MD; Truong, TT | 1 |
| Chia, A; Farooqui, SZ; Foo, LL; Htoon, H | 1 |
| Chen, LJ; Kam, KW; Li, FF; Pang, CP; Tang, SM; Tham, CC; Yam, JC; Young, AL; Zhang, Y | 1 |
| Azad, AK; Mulik, S; Paidipally, P; Radhakrishnan, RK; Samten, B; Schlesinger, LS; Sivangala Thandi, R; Tripathi, D; Vankayalapati, R | 1 |
| Chiu, CJ; Tsai, WS; Wang, JH | 1 |
| Driessen, S; Klaver, CCW; Loudon, SE; Polling, JR; Tan, E; Tideman, JWL; van der Schans, A; Wong, HL | 1 |
| Repka, MX | 1 |
| An, W; Du, J; Li, SM; Liang, X; Sun, Y; Tian, J; Wang, N; Wei, S; Zhang, D | 1 |
| Gao, C; Han, J; Wan, S; Zhang, Y | 1 |
| Chiang, ST; Phillips, JR; Turnbull, PRK | 1 |
| Brennan, NA; Bullimore, MA; Cheng, X; Toubouti, YM | 1 |
| Cai, C; Dai, H; Ding, Q; Zhao, C | 1 |
| Dhiman, R; Gupta, V; Kumar, P; Matalia, J; Phuljhele, S; Roy, L; Saxena, R; Sharma, N; Swaminathan, M; Velpandian, T | 1 |
| Fujikado, T; Hasebe, S; Hieda, O; Hiraoka, T; Ishiko, S; Kinoshita, S; Kurihara, T; Morimoto, T; Nakai, T; Nakamura, Y; Negishi, K; Nishi, Y; Nishida, K; Nishikawa, N; Ono, M; Oshika, T; Shigeno, Y; Song, YS; Sotozono, C; Takahashi, H; Tan, D; Tanaka, S; Tokutake, T; Torii, H; Tsubota, K | 1 |
| Bleul, T; Böhringer, D; Farassat, N; Joachimsen, L; Lagrèze, WA; Reich, M | 1 |
| Chen, DX; He, XG; Xu, X | 1 |
| Allen, PM; Gopalakrishnan, A; Hussaindeen, JR; Sivaraman, V; Swaminathan, M | 1 |
| Cui, C; Fu, A; Lyu, Y; Stapleton, F; Wang, W; Watt, K; Wei, L; Yu, S; Zhao, B | 1 |
| Graff, B; Kaymak, H; Langenbucher, A; Schaeffel, F; Schwahn, H; Seitz, B | 1 |
| Erdinest, N; Lavy, I; Levinger, N; London, N; Morad, Y; Pras, E | 1 |
| Graham, SL; Rose, LVT; Schulz, AM | 1 |
| Dalal, DM; Jethani, J | 1 |
| Han, JR; Hong, IH; Jeon, GS; Lee, JH; Lee, TY; Song, TG | 1 |
| Coroneo, M; Ha, TTX; Jong, M; Naduvilath, T; Sankaridurg, P; Tran, HDM; Tran, TD; Tran, YH | 1 |
| Chen, B; Gong, Q; Janowski, M; Liu, L; Luo, M; Wei, H; Yang, G | 1 |
| Galvin, JA; Hutchinson, AK; Kraker, RT; Lambert, SR; Pineles, SL; VanderVeen, DK; Wilson, LB | 1 |
| Lagrèze, WA; Schaeffel, F | 1 |
| Kothari, M; Rathod, V | 1 |
| Erdinest, N; Morad, Y | 1 |
| Schittkowski, MP; Sturm, V | 1 |
| Diaz-Llopis, M; Pinazo-Durán, MD | 1 |
| Cooper, J; Tkatchenko, AV | 1 |
| Cisneros Lanuza, A; Díaz Llopis, M | 1 |
| Hamada, N; Kakehashi, A; Kanda, Y; Kinoshita, N; Konno, Y; Shimmura-Tomita, M | 1 |
| Brown, DD; Guo, S; Wagner, RS; Wang, FM | 1 |
| Chan, JJ; Chen, LJ; Jiang, Y; Ko, ST; Law, AKP; Pang, CP; Tang, SM; Tham, CC; Wong, E; Yam, JC; Young, AL | 1 |
| Díaz Llopis, M | 1 |
| Chen, LJ; Lee, SM; Mak, CY; Yam, JC; Young, AL | 1 |
| Sankaridurg, P; Tran, HDM | 1 |
| Hoang, QV; Matsumura, S; Saw, SM | 1 |
| Wagner, RS | 1 |
| Kesarwani, SS | 1 |
| Park, S; Weiss, RS | 1 |
| Ohno-Matsui, K; Vutipongsatorn, K; Yokoi, T | 1 |
| Bonsignore, F; Luccarelli, S; Nucci, P; Sacchi, M; Serafino, M; Tagliabue, E; Villani, E | 1 |
| Brennan, NA; Cheng, X | 1 |
| Han, WT; Rong, A; Xu, W | 1 |
| Inoue, M; Koike, Y; Kusunoki, M; Nakazawa, M; Tsukamoto, Y; Uchida, K | 1 |
| Ducharme, FM; Griffiths, B | 1 |
| Chia, A; Chua, WH; Fong, A; Goon, YY; Tan, D; Wen, L | 1 |
| Bendtsen, F; Dahl, EK; Kjær, A; Krag, A; Møller, S; Petersen, CL | 1 |
| Aller, TA | 1 |
| Chen, W; Jia, SM; Kang, MT; Li, H; Li, SM; Li, SY; Liu, LR; Liu, Y; Millodot, M; Sun, YY; Wang, N; Wu, SS; Yang, Z; Zhan, SY | 1 |
| Chu, R; Dai, J; Liu, H; Liu, R; Zhang, X; Zhou, H; Zou, L | 1 |
| Chia, A; Loh, KL; Lu, Q; Tan, D | 1 |
| Clark, RA; Clark, TY | 1 |
| Chia, A; Lu, QS; Tan, D | 1 |
| Chia, A; Htoon, HM; Kumaran, A; Tan, D | 1 |
| Chan, TC; Cheng, AC; Fan, DS; Lai, JS; Li, WW; Ng, AL; Shih, KC | 1 |
| Klaver, CC; Kok, RG; Meskat, B; Polling, JR; Tideman, JW | 1 |
| Lee, CY; Lin, KK; Lin, YF; Sun, CC | 1 |
| Chang, CY; Chen, HJ; Chen, TH; Hsieh, YC; Hsu, YA; Lin, HJ; Wan, L; Wei, CC | 1 |
| Joachimsen, L; Lagrèze, WA; Schaeffel, F | 1 |
| Gong, Q; Liu, L | 1 |
| Schaeffel, F | 2 |
| Iribarren, R | 1 |
| Chua, WH; Huang, XL; Koh, AL; Tan, DT; Tong, L; Zhang, X | 1 |
| Chia, A; Chua, WH; Tan, D | 1 |
| Abou-Donia, MB; Attia, MK; Damodaran, TV; Gupta, RP | 1 |
| Brown, SM | 1 |
| Chung, MY; Fang, PC; Wu, PC; Yu, HJ | 1 |
| Chen, Z; Li, T; Xu, Y; Yao, P; Zhou, X | 1 |
| Leo, SW; Young, TL | 1 |
| Chen, HZ; Qi, H; Rong, ZX; Song, YY; Wang, BS; Wang, H | 1 |
| Fang, PC; Wu, PC; Yang, YH | 1 |
| Baek, SH; Gong, SM; Jung, JJ; Kim, US; Kim, YR; Lim, EH | 1 |
| Cotter, SA; Lindsley, K; Mutti, DO; Twelker, JD; Vedula, SS; Walline, JJ | 1 |
| Chen, WC; Lin, CJ; Lin, HJ; Lin, JM; Tsai, FJ; Wan, L | 1 |
| Au Eong, KG; Gazzard, G; Saw, SM; Tan, DT | 1 |
| Kirschen, D; London, R; Wick, B | 1 |
| Botella, LM; Cabello, G; Calaf, GM; Juarranz, A | 1 |
| Gordonson, LC | 1 |
| Chen, CH; Fang, PC; Kuo, HK; Lee, JJ; Lin, PW; Lin, SA; Wu, PC; Yang, IH | 1 |
| Cattaneo, V; Colombo, L; de la Torre, E; Español, A; Fiszman, G; Sacerdote de Lustig, E; Sales, ME | 1 |
| Afendulov, SA; Krasnolutskiĭ, NA; Smirnov, AD; Zhuravlev, GIu | 1 |
| Kennedy, RH | 1 |
| Chou, AC; Ho, TC; Lin, LL; Shih, YF | 1 |
| Chen, CH; Chou, AC; Ho, TC; Hung, PT; Lin, LL; Shih, YF | 1 |
| Braun, W; Lauer, MS; Lobo, A; Marwick, TH; Nally, J | 1 |
| Donovan, JP; Romano, PE | 1 |
| Chang, CW; Chen, CJ; Hsiao, CK; Hung, PT; Lin, LL; Shih, YF | 1 |
| Dyer, JA; Herman, DC; Jacobs, D; Kennedy, MA; Kennedy, RH; Kurland, LT; Luepker, RV; McIntire, D; Parulkar, S | 1 |
| Isenberg, SJ; Syniuta, LA | 1 |
| Chiang, MF; Kouzis, A; Pointer, RW; Repka, MX | 1 |
| Romano, PE | 1 |
| Koh, A; Saw, SM; Shih-Yen, EC; Tan, D | 1 |
40 review(s) available for atropine and Disease Exacerbation
| Article | Year |
|---|---|
Vision-related quality of life with myopia management: A review.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; Humans; Incidence; Myopia; Orthokeratologic Procedures; Quality of Life; Refraction, Ocular | 2022 |
China Turns to School Reform to Control the Myopia Epidemic: A Narrative Review.
Topics: Atropine; China; Disease Progression; Eyeglasses; Humans; Myopia; Schools | 2022 |
Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia.
Topics: Atropine; Contact Lenses, Hydrophilic; Disease Progression; Eye; Humans; Myopia; Refraction, Ocular | 2023 |
Multiple Factors Causing Myopia and the Possible Treatments: A Mini Review.
Topics: Atropine; COVID-19; Disease Progression; Humans; Myopia; Ophthalmic Solutions | 2022 |
Current concepts in the management of childhood myopia.
Topics: Atropine; Contact Lenses; Disease Progression; Eyeglasses; Humans; Myopia | 2022 |
Efficacy of 0.01% Atropine Eye Drops in Controlling Myopia Progression and Axial Elongation in Children: A Meta-analysis Based on Randomized Controlled Trials.
Topics: Atropine; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Randomized Controlled Trials as Topic | 2022 |
Topical Review: Studies on Management of Myopia Progression from 2019 to 2021.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; Eyeglasses; Humans; Myopia; Orthokeratologic Procedures; Refraction, Ocular; Retrospective Studies | 2023 |
Acceptability of 8 atropine concentrations for myopia control in children: a network meta-analysis.
Topics: Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Network Meta-Analysis; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Myopia prevention and control in children: a systematic review and network meta-analysis.
Topics: Atropine; Axial Length, Eye; Child; Contact Lenses, Hydrophilic; Disease Progression; Humans; Myopia; Network Meta-Analysis; Refraction, Ocular | 2023 |
Efficacy and safety of atropine in myopic children: A meta-analysis of randomized controlled trials.
Topics: Atropine; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Randomized Controlled Trials as Topic; Refraction, Ocular | 2023 |
Incidence of Adverse Events Induced by Atropine in Myopic Children: A Meta-Analysis.
Topics: Atropine; Child; Disease Progression; Humans; Incidence; Mydriatics; Myopia; Ophthalmic Solutions; Photophobia | 2023 |
Repeated Low-Level Red Light Therapy for the Control of Myopia in Children: A Meta-Analysis of Randomized Controlled Trials.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; Humans; Mydriatics; Myopia; Phototherapy; Randomized Controlled Trials as Topic; Refraction, Ocular | 2023 |
Preventing the Progression of Myopia in Children-A Review of the Past Decade.
Topics: Atropine; Child; Disease Progression; Eyeglasses; Humans; Myopia | 2023 |
Which low-dose atropine for myopia control?
Topics: Atropine; Disease Progression; Dose-Response Relationship, Drug; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2020 |
Biological Mechanisms of Atropine Control of Myopia.
Topics: Atropine; Child; Disease Progression; Humans; Muscarinic Antagonists; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2020 |
The Efficacy of Atropine Combined With Orthokeratology in Slowing Axial Elongation of Myopia Children: A Meta-Analysis.
Topics: Adolescent; Atropine; Axial Length, Eye; Child; Disease Progression; Humans; Myopia; Orthokeratologic Procedures; Refraction, Ocular | 2021 |
Efficacy in myopia control.
Topics: Adolescent; Atropine; Child; Disease Progression; Eyeglasses; Humans; Myopia; Refraction, Ocular; Vision Tests | 2021 |
Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis.
Topics: Atropine; Disease Progression; Humans; Myopia | 2020 |
A Meta-Analysis Assessing Change in Pupillary Diameter, Accommodative Amplitude, and Efficacy of Atropine for Myopia Control.
Topics: Atropine; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2021 |
Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis.
Topics: Atropine; Child; Disease Progression; Dose-Response Relationship, Drug; Humans; Mydriatics; Myopia; Refraction, Ocular | 2017 |
Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Atropine; Child; Child, Preschool; Databases, Factual; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Ophthalmology; Technology Assessment, Biomedical; Treatment Outcome; United States | 2017 |
[TREATMENTS FOR SLOWING THE PROGRESSION OF MYOPIA].
Topics: Atropine; Contact Lenses, Hydrophilic; Disease Progression; Eyeglasses; Humans; Myopia; Timolol | 2017 |
[Atropine for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines].
Topics: Age Factors; Atropine; Axial Length, Eye; Child; Disease Progression; Follow-Up Studies; Guideline Adherence; Humans; Myopia; Ophthalmic Solutions; Prospective Studies; Randomized Controlled Trials as Topic; Refraction, Ocular | 2018 |
A Review of Current Concepts of the Etiology and Treatment of Myopia.
Topics: Atropine; Contact Lenses; Disease Progression; Eyeglasses; Humans; Muscarinic Antagonists; Mydriatics; Myopia; Orthokeratologic Procedures; Recreation | 2018 |
Epidemiology of myopia and prevention of myopia progression in children in East Asia: a review.
Topics: Administration, Ophthalmic; Asia, Eastern; Atropine; Child; Contact Lenses; Disease Progression; Eyeglasses; Hong Kong; Humans; Muscarinic Antagonists; Myopia; Pirenzepine; Prevalence | 2018 |
Consensus statement and guidelines for use of dilute atropine sulphate in myopia control.
Topics: Atropine; Consensus; Disease Progression; Humans; Mydriatics; Myopia, Degenerative; Ophthalmic Solutions; Practice Guidelines as Topic; Refraction, Ocular; Treatment Outcome | 2019 |
Recent updates on myopia control: preventing progression 1 diopter at a time.
Topics: Atropine; Axial Length, Eye; Child; Contact Lenses; Disease Progression; Eyeglasses; Humans; Mydriatics; Myopia; Orthokeratologic Procedures | 2019 |
Current and emerging pharmaceutical interventions for myopia.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atropine; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy; Humans; Ketorolac Tromethamine; Mydriatics; Myopia; Pharmaceutical Preparations; Riboflavin; Vitamin B Complex; Xanthines | 2019 |
Commonly Held Beliefs About Myopia That Lack a Robust Evidence Base.
Topics: Atropine; Child; Computers, Handheld; Disease Progression; Environmental Exposure; Evidence-Based Medicine; Eyeglasses; Humans; Hyperopia; Mydriatics; Myopia | 2019 |
Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Asthma; Atropine; Child; Child, Preschool; Cholinergic Antagonists; Disease Progression; Drug Therapy, Combination; Hospitalization; Humans; Infant; Ipratropium; Randomized Controlled Trials as Topic | 2013 |
Clinical management of progressive myopia.
Topics: Atropine; Contact Lenses; Disease Progression; Humans; Mydriatics; Myopia; Orthokeratologic Procedures | 2014 |
Atropine slows myopia progression more in Asian than white children by meta-analysis.
Topics: Adolescent; Asian People; Atropine; Child; Child, Preschool; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Observational Studies as Topic; Odds Ratio; Randomized Controlled Trials as Topic; White People | 2014 |
Use of Atropine for Prevention of Childhood Myopia Progression in Clinical Practice.
Topics: Atropine; Child; Child, Preschool; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Randomized Controlled Trials as Topic | 2016 |
[Current recommendations for deceleration of myopia progression].
Topics: Atropine; Combined Modality Therapy; Contact Lenses; Disease Progression; Evidence-Based Medicine; Germany; Humans; Myopia; Ophthalmic Solutions; Ophthalmology; Phototherapy; Practice Guidelines as Topic; Secondary Prevention; Treatment Outcome | 2017 |
[Biological mechanisms of myopia].
Topics: Animals; Atropine; Disease Progression; Evidence-Based Medicine; Humans; Lighting; Myopia; Photic Stimulation; Phototherapy; Refraction, Ocular; Retina; Treatment Outcome | 2017 |
Atropine in ameliorating the progression of myopia in children with mild to moderate myopia: a meta-analysis of controlled clinical trials.
Topics: Adolescent; Atropine; Child; Child, Preschool; Controlled Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Regression Analysis; Retrospective Studies | 2011 |
[Myopia update 2011].
Topics: Aged; Atropine; Axial Length, Eye; Contact Lenses; Disease Progression; Eyeglasses; Follow-Up Studies; Humans; Intravitreal Injections; Muscarinic Antagonists; Myopia; Prognosis; Retina; Retinal Degeneration; Sclera; Scleral Buckling; Tissue Inhibitor of Metalloproteinase-2; Vascular Endothelial Growth Factor A; Visual Acuity; Visual Fields | 2011 |
Interventions to slow progression of myopia in children.
Topics: Atropine; Child; Contact Lenses; Cyclopentolate; Disease Progression; Eyeglasses; Humans; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Pirenzepine; Randomized Controlled Trials as Topic | 2011 |
Myopia: attempts to arrest progression.
Topics: Accommodation, Ocular; Adolescent; Adult; Atropine; Biofeedback, Psychology; Child; Contact Lenses; Disease Progression; Eye Movements; Eyeglasses; Humans; Intraocular Pressure; Medicine, Chinese Traditional; Myopia; Ophthalmic Solutions; Pirenzepine; Timolol; Tropicamide | 2002 |
Interventions to retard myopia progression in children: an evidence-based update.
Topics: Atropine; Child; Child, Preschool; Contact Lenses, Hydrophilic; Databases, Factual; Disease Progression; Evidence-Based Medicine; Eyeglasses; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Randomized Controlled Trials as Topic; Timolol; Tropicamide | 2002 |
38 trial(s) available for atropine and Disease Exacerbation
| Article | Year |
|---|---|
A multicenter Spanish study of atropine 0.01% in childhood myopia progression.
Topics: Adolescent; Atropine; Child; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Prospective Studies | 2021 |
Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops.
Topics: Atropine; Axial Length, Eye; Child; Child, Preschool; Cornea; Disease Progression; Double-Blind Method; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2021 |
Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes.
Topics: Atropine; Axial Length, Eye; Case-Control Studies; Child; Child, Preschool; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2022 |
Re: Saxena et al.: Atropine for the treatment of childhood myopia in India: multicentric randomized trial. (Ophthalmology. 2021;128:1367-1369).
Topics: Atropine; Disease Progression; Humans; India; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2022 |
Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular; Vision Tests | 2022 |
Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial.
Topics: Atropine; Axial Length, Eye; Child; Cross-Over Studies; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Effect of atropine 0.01% on progression of myopia.
Topics: Atropine; Axial Length, Eye; Case-Control Studies; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Prospective Studies; Refraction, Ocular; Single-Blind Method | 2022 |
Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial.
Topics: Adolescent; Atropine; Australia; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2022 |
Low Dose Atropine in Preventing the Progression of Childhood Myopia: A Randomised Controlled Trial.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial.
Topics: Age of Onset; Atropine; Child; Child, Preschool; Disease Progression; Double-Blind Method; Female; Humans; Incidence; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine.
Topics: Adolescent; Atropine; Child; Disease Progression; Eyeglasses; Humans; Myopia; Prospective Studies; Refraction, Ocular | 2023 |
Multifocal Contact Lenses and 0.01% Atropine Eye Drops for Myopia Control Study: Research Protocol for a 1-Year, Randomized, Four-Arm, Clinical Trial in Schoolchildren.
Topics: Atropine; Axial Length, Eye; Child; Contact Lenses; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Prospective Studies; Randomized Controlled Trials as Topic; Refraction, Ocular | 2023 |
Effect of 0.01% Atropine on diopter and optic axis in adolescents and children with myopia.
Topics: Adolescent; Atropine; Child; Disease Progression; Eyeglasses; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective, randomized, double-masked, and crossover trial.
Topics: Atropine; Child; Cross-Over Studies; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Prospective Studies | 2023 |
Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; East Asian People; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety.
Topics: Atropine; Axial Length, Eye; Child; Denmark; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Use of Topical 0.01% Atropine for Controlling Near Work-Induced Transient Myopia: A Randomized, Double-Masked, Placebo-Controlled Study.
Topics: Administration, Topical; Adolescent; Asian People; Atropine; Child; Disease Progression; Double-Blind Method; Female; Humans; Male; Myopia; Ophthalmic Solutions; Reading; Vision Tests | 2020 |
Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report.
Topics: Accommodation, Ocular; Administration, Topical; Atropine; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mydriatics; Myopia, Degenerative; Ophthalmic Solutions; Refraction, Ocular; Time Factors; Visual Acuity | 2020 |
Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression.
Topics: Accommodation, Ocular; Administration, Ophthalmic; Adolescent; Atropine; Axial Length, Eye; Child; Disease Progression; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Visual Acuity | 2020 |
Western Australia Atropine for the Treatment of Myopia (WA-ATOM) study: Rationale, methodology and participant baseline characteristics.
Topics: Atropine; Australia; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular; Western Australia | 2020 |
Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.
Topics: Accommodation, Ocular; Administration, Ophthalmic; Astigmatism; Atropine; Axial Length, Eye; Biometry; Child; Child, Preschool; Cornea; Disease Progression; Double-Blind Method; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Visual Acuity | 2020 |
Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial.
Topics: Accommodation, Ocular; Atropine; Axial Length, Eye; Child; China; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Male; Mydriatics; Myopia, Degenerative; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies; Treatment Outcome; Visual Acuity | 2020 |
Additive effect of atropine eye drops and short-term retinal defocus on choroidal thickness in children with myopia.
Topics: Adolescent; Atropine; Child; Choroid; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Retina | 2020 |
Atropine for the Treatment of Childhood Myopia in India: Multicentric Randomized Trial.
Topics: Accommodation, Ocular; Administration, Ophthalmic; Adolescent; Atropine; Child; Disease Progression; Double-Blind Method; Female; Humans; India; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Visual Acuity | 2021 |
Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study.
Topics: Accommodation, Ocular; Atropine; Child; Disease Progression; Humans; Myopia, Degenerative; Ophthalmic Solutions; Refraction, Ocular; Visual Acuity | 2021 |
Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness.
Topics: Adolescent; Atropine; Child; Disease Progression; Female; Humans; Male; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Prospective Studies; Time Factors; Treatment Outcome | 2018 |
Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results.
Topics: Atropine; Axial Length, Eye; Child; Cornea; Corneal Topography; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Interferometry; Male; Mydriatics; Myopia; Ophthalmic Solutions; Orthokeratologic Procedures; Prospective Studies; Refraction, Ocular; Time Factors; Treatment Outcome | 2018 |
Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
Topics: Accommodation, Ocular; Administration, Ophthalmic; Atropine; Axial Length, Eye; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Quality of Life; Refraction, Ocular; Surveys and Questionnaires; Vision Tests; Visual Acuity | 2019 |
Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.
Topics: Accommodation, Ocular; Administration, Topical; Atropine; Axial Length, Eye; Child; Disease Progression; Double-Blind Method; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Prospective Studies; Pupil; Visual Acuity; Withholding Treatment | 2014 |
Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study.
Topics: Adolescent; Adult; Aged; Atrial Natriuretic Factor; Atropine; Autonomic Nervous System; Biomarkers; Blood Pressure; Cardiac Output; Case-Control Studies; Disease Progression; Dobutamine; Electrocardiography; Female; Heart; Heart Rate; Humans; Liver Cirrhosis; Male; Middle Aged; Myocardial Contraction; Parasympatholytics; Severity of Illness Index; Stress, Physiological; Sympathomimetics; Young Adult | 2014 |
Risk factors for progressive myopia in the atropine therapy for myopia study.
Topics: Accommodation, Ocular; Administration, Topical; Atropine; Child; Cohort Studies; Disease Progression; Double-Blind Method; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Pupil; Refraction, Ocular; Retrospective Studies; Risk Factors; Surveys and Questionnaires; Visual Acuity | 2015 |
Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops.
Topics: Accommodation, Ocular; Administration, Topical; Atropine; Axial Length, Eye; Child; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Pupil | 2016 |
Analysis of Changes in Refraction and Biometry of Atropine- and Placebo-Treated Eyes.
Topics: Anterior Chamber; Atropine; Biometry; Child; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Time Factors; Vision Tests | 2015 |
Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
Topics: Accommodation, Ocular; Administration, Topical; Atropine; Child; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Visual Acuity; Withholding Treatment | 2009 |
Effect of topical atropine on astigmatism.
Topics: Astigmatism; Atropine; Child; Corneal Topography; Disease Progression; Female; Humans; Male; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Refraction, Ocular; Treatment Failure | 2009 |
Effects of different concentrations of atropine on controlling myopia in myopic children.
Topics: Adolescent; Atropine; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Visual Acuity | 1999 |
An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression.
Topics: Adolescent; Atropine; Child; Disease Progression; Double-Blind Method; Eyeglasses; Female; Follow-Up Studies; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions | 2001 |
Atropine and bifocals can slow the progression of myopia in children.
Topics: Adolescent; Atropine; Child; Child, Preschool; Disease Progression; Eyeglasses; Female; Humans; Male; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Visual Acuity | 2001 |
83 other study(ies) available for atropine and Disease Exacerbation
| Article | Year |
|---|---|
Stepwise low concentration atropine for myopic control: a 10-year cohort study.
Topics: Atropine; Child; Child, Preschool; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies; Risk Factors; Treatment Outcome; Vision Tests | 2021 |
Parasympathetic, but not sympathetic denervation, suppressed colorectal cancer progression.
Topics: 1,2-Dimethylhydrazine; Animals; Atropine; Carcinogenesis; Carcinogens; Colon; Colorectal Neoplasms; Disease Progression; Ganglia, Sympathetic; Ganglionectomy; Guanethidine; Humans; Male; Mesentery; Neoplasms, Experimental; Parasympathetic Nervous System; Rats; Rats, Wistar; Vagotomy | 2021 |
Symptoms and ocular findings associated with administration of 0.01% atropine in young adults.
Topics: Accommodation, Ocular; Adult; Atropine; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Pupil; Refraction, Ocular; Young Adult | 2023 |
Update on Myopia Control: The US Perspective.
Topics: Atropine; Contact Lenses; Disease Progression; Eyeglasses; Humans; Myopia; Orthokeratologic Procedures | 2022 |
Trends in myopia management attitudes and strategies in clinical practice: Survey of eye care practitioners in Africa.
Topics: Africa; Atropine; Child; Contact Lenses, Hydrophilic; Disease Progression; Humans; Myopia; Surveys and Questionnaires | 2023 |
Effect of Combining 0.01% Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children.
Topics: Atropine; Child; Contact Lenses, Hydrophilic; Disease Progression; Eyeglasses; Humans; Myopia; Refraction, Ocular | 2022 |
Characteristics of responders to atropine 0.01% as treatment in Asian myopic children.
Topics: Adolescent; Atropine; Child; Child, Preschool; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies | 2022 |
Compounding of Low-Concentration Atropine for Myopia Control.
Topics: Atropine; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; United States; United States Food and Drug Administration | 2022 |
[Progression of Myopia - which Preventive Measures Can be Recommended?]
Topics: Atropine; Child; Contact Lenses; Disease Progression; Eye; Humans; Myopia; Refraction, Ocular | 2023 |
Retrospective Analysis of a Clinical Algorithm for Managing Childhood Myopia Progression.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; Humans; Mydriatics; Myopia; Orthokeratologic Procedures; Refraction, Ocular; Retrospective Studies | 2023 |
Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia.
Topics: Adenosine Triphosphate; Adolescent; Atropine; Child; Disease Progression; Eyeglasses; Humans; Myopia; Refraction, Ocular; Retrospective Studies | 2022 |
Efficacy in Myopia Control: The Low-Concentration Atropine for Myopia Progression (LAMP) Study.
Topics: Atropine; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Myopia control and prevention: From lifestyle to low-concentration atropine. The 2022 Josh Wallman Memorial Lecture.
Topics: Atropine; Child; COVID-19; Disease Progression; Humans; Life Style; Mydriatics; Myopia; Ophthalmic Solutions; Pandemics; Refraction, Ocular | 2023 |
Myopia control in Mendelian forms of myopia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Disease Progression; Female; Humans; Male; Mice; Mice, Inbred C57BL; Myopia, Degenerative; Ophthalmic Solutions; Refraction, Ocular; Retina | 2023 |
[[A MULTICENTER SPANISH STUDY OF ATROPINE 0.01% IN CHILDHOOD MYOPIA PROGRESSION]].
Topics: Atropine; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Prevalence | 2023 |
IMI 2023 Digest.
Topics: Atropine; Combined Modality Therapy; Contact Lenses, Hydrophilic; Disease Progression; Humans; Myopia; Refraction, Ocular | 2023 |
Low-concentration atropine: Co-management of myopia in children and young people in the UK - prospective case series.
Topics: Adolescent; Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; United Kingdom | 2023 |
Cochrane corner: interventions for myopia control in children.
Topics: Atropine; Child; Disease Progression; Humans; Myopia; Refraction, Ocular | 2023 |
Myopia Management in Daily Routine - A Survey of European Pediatric Ophthalmologists.
Topics: Atropine; Child; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Ophthalmologists; Refraction, Ocular; Surveys and Questionnaires | 2023 |
Effectiveness of 0.01% atropine in anisomyopic children.
Topics: Atropine; Axial Length, Eye; Child; Disease Progression; Eye; Humans; Mydriatics; Myopia; Refraction, Ocular; Retrospective Studies | 2023 |
Low-Concentration Atropine Eyedrops for Myopia in Children-Reply.
Topics: Atropine; Child; Disease Progression; Humans; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Low-Concentration Atropine Eyedrops for Myopia in Children.
Topics: Atropine; Child; Disease Progression; Humans; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Myopia control: short-term effect of 0.01% atropine vs. defocus incorporated multiple segment lenses-a retrospective study in European children.
Topics: Atropine; Child; Disease Progression; Eyeglasses; Humans; Myopia; Refraction, Ocular; Retrospective Studies | 2023 |
Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial.
Topics: Atropine; Child; Child, Preschool; Disease Progression; Female; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular; Vision Tests | 2023 |
Atropine, 0.01%, for Myopia Control.
Topics: Atropine; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2023 |
Real-world outcomes of low-dose atropine therapy on myopia progression in an Australian cohort during the COVID-19 pandemic.
Topics: Adolescent; Atropine; Australia; Axial Length, Eye; Child; COVID-19; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Pandemics; Refraction, Ocular; Retrospective Studies | 2023 |
Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression.
Topics: Administration, Topical; Adolescent; Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Prospective Studies; Refraction, Ocular | 2023 |
Practice patterns to decrease myopia progression differ among paediatric ophthalmologists around the world.
Topics: Atropine; Behavior Therapy; Child, Preschool; Disease Progression; Eyeglasses; Female; Global Health; Humans; Male; Mydriatics; Myopia; Ophthalmologists; Pediatrics; Pirenzepine; Practice Patterns, Physicians'; Surveys and Questionnaires | 2020 |
Will the long-term use of atropine eye drops in children increase the risk of dry eye?
Topics: Animals; Atropine; Child; China; Disease Models, Animal; Disease Progression; Dry Eye Syndromes; Humans; Myopia; Ophthalmic Solutions; Patient Safety; Rabbits; Risk | 2019 |
Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children.
Topics: Accommodation, Ocular; Administration, Topical; Atropine; Child; China; Disease Progression; Female; Humans; Male; Myopia; Ophthalmic Solutions; Refraction, Ocular; Visual Acuity | 2020 |
Part-time use of 1% atropine eye drops for prevention of myopia progression in children.
Topics: Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies | 2020 |
Ornithine-A urea cycle metabolite enhances autophagy and controls Mycobacterium tuberculosis infection.
Topics: Ammonia; Animals; Apoptosis; Arginase; Atropine; Autophagy; Cell Proliferation; Disease Progression; Female; Imidazoles; Kupffer Cells; Macrophages, Alveolar; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Nitric Oxide; Ornithine; Phosphatidylserines; Reactive Oxygen Species; RNA, Small Interfering; Tuberculosis; Urea | 2020 |
A comparative study of orthokeratology and low-dose atropine for the treatment of anisomyopia in children.
Topics: Adolescent; Anisometropia; Atropine; Axial Length, Eye; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Muscarinic Antagonists; Myopia; Orthokeratologic Procedures; Retrospective Studies; Treatment Outcome | 2020 |
A 3-year follow-up study of atropine treatment for progressive myopia in Europeans.
Topics: Adult; Atropine; Child; Disease Progression; Follow-Up Studies; Humans; Myopia, Degenerative; Ophthalmic Solutions; Prospective Studies; Refraction, Ocular | 2020 |
Myopia Control With Low-Dose Atropine Eyedrops.
Topics: Atropine; Child; China; Disease Progression; Humans; Myopia; Ophthalmic Solutions | 2020 |
Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study.
Topics: Atropine; Child; Disease Progression; Double-Blind Method; Humans; Mydriatics; Ophthalmic Solutions; Pilot Projects; Schools | 2021 |
[The safety of atropine for myopia prevention and control].
Topics: Amblyopia; Atropine; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Optometry | 2021 |
Efficacy of low-dose atropine to reduce myopia progression among Indian children.
Topics: Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions | 2021 |
Risk factors for rapid axial length elongation with low concentration atropine for myopia control.
Topics: Administration, Ophthalmic; Atropine; Axial Length, Eye; Disease Progression; Female; Humans; Male; Myopia; Odds Ratio; Refraction, Ocular; Risk Assessment; Risk Factors | 2021 |
A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting.
Topics: Adolescent; Atropine; Axial Length, Eye; Biometry; Child; Child, Preschool; Disease Progression; Humans; Mydriatics; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies | 2021 |
Decreased effectiveness of 0.01% atropine treatment for myopia control during prolonged COVID-19 lockdowns.
Topics: Adolescent; Atropine; Axial Length, Eye; Child; Communicable Disease Control; COVID-19; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Pandemics; Refraction, Ocular; Retrospective Studies | 2022 |
Use baseline axial length measurements in myopic patients to predict the control of myopia with and without atropine 0.01.
Topics: Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia, Degenerative; Refraction, Ocular | 2021 |
Compliance in usage of low-dose atropine for prevention of progression of myopia in Indian children.
Topics: Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2021 |
Analysis of treatment response about low-dose (0.01%) atropine eye-drops in myopic children.
Topics: Adolescent; Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies | 2022 |
Preventing Myopia.
Topics: Atropine; Disease Progression; Humans; Meta-Analysis as Topic; Myopia; Randomized Controlled Trials as Topic; Visual Acuity | 2017 |
Efficacy of 1% atropine eye drops in retarding progressive axial myopia in Indian eyes.
Topics: Adolescent; Atropine; Child; Child, Preschool; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Prospective Studies; Refraction, Ocular; Treatment Outcome; Visual Acuity | 2017 |
Myopia, the challenge of Ophthalmology and its worldwide "explosive epidemic".
Topics: Adolescent; Adult; Age of Onset; Atropine; Child; Contact Lenses; Disease Progression; Eyeglasses; Humans; Incidence; Life Style; Lighting; Morbidity; Myopia; Ophthalmic Solutions; Risk Factors; Sunlight | 2018 |
Management of High Myopia in Children.
Topics: Atropine; Disease Management; Disease Progression; Dose-Response Relationship, Drug; Eyeglasses; Humans; Infant; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2018 |
Author's reply.
Topics: Adolescent; Atropine; Child; Disease Progression; Humans; Myopia | 2019 |
The Lowdown on Low-Concentration Atropine for Myopia Progression.
Topics: Atropine; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions | 2019 |
Prevention and Management of Myopia and Myopic Pathology.
Topics: Atropine; Blindness; Contact Lenses, Hydrophilic; Cross-Linking Reagents; Disease Progression; Humans; Muscarinic Antagonists; Myopia; Myopia, Degenerative; Ophthalmologic Surgical Procedures; Orthokeratologic Procedures | 2019 |
Treatment of Progressive Myopia in the Pediatric Population.
Topics: Atropine; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Global Health; Humans; Incidence; Mydriatics; Myopia, Degenerative; Ophthalmic Solutions; Refraction, Ocular | 2019 |
Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients.
Topics: Adolescent; Atropine; Child; Child, Preschool; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Italy; Male; Mydriatics; Myopia, Degenerative; Ophthalmic Solutions; Prevalence; Refraction, Ocular; Retrospective Studies; Treatment Outcome | 2019 |
[Combination with different anticholinergic eyedrops for the treatment of children myopia].
Topics: Adolescent; Aged; Atropine; Child; China; Cholinergic Antagonists; Disease Progression; Humans; Myopia; Ophthalmic Solutions; Refraction, Ocular | 2019 |
Predictive factors of negative outcome in initial atropine therapy for infantile hypertrophic pyloric stenosis.
Topics: Administration, Oral; Atropine; Disease Progression; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Injections, Intravenous; Male; Parasympatholytics; Prognosis; Pyloric Stenosis, Hypertrophic; Retrospective Studies; Risk Factors; Treatment Failure | 2013 |
Upregulation of regulator of G-protein signaling 2 in the sclera of a form deprivation myopic animal model.
Topics: Animals; Atropine; Collagen Type I; Disease Models, Animal; Disease Progression; Down-Regulation; Guinea Pigs; Myopia; Phenotype; Real-Time Polymerase Chain Reaction; Reproducibility of Results; RGS Proteins; Sclera; Sensory Deprivation; Up-Regulation | 2014 |
Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia.
Topics: Administration, Ophthalmic; Adolescent; Atropine; Case-Control Studies; Child; Disease Progression; Female; Follow-Up Studies; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Retrospective Studies; Treatment Outcome | 2015 |
Effectiveness study of atropine for progressive myopia in Europeans.
Topics: Administration, Topical; Adolescent; Atropine; Axial Length, Eye; Child; Disease Progression; Female; Humans; Male; Medication Adherence; Muscarinic Antagonists; Myopia, Degenerative; Netherlands; Ophthalmic Solutions; Refraction, Ocular; Treatment Outcome; White People | 2016 |
Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study.
Topics: Analysis of Variance; Atropine; Case-Control Studies; Child; Disease Progression; Female; Humans; Intraocular Pressure; Male; Mydriatics; Myopia; Prospective Studies; Taiwan; Tonometry, Ocular | 2016 |
Role of Chronic Inflammation in Myopia Progression: Clinical Evidence and Experimental Validation.
Topics: Adolescent; Animals; Anti-Inflammatory Agents; Atropine; Cell Culture Techniques; Child; Child, Preschool; Cohort Studies; Comorbidity; Cricetinae; Disease Models, Animal; Disease Progression; Female; Gene Expression Profiling; Humans; Incidence; Infant; Inflammation; Male; Myopia; Population Surveillance; Taiwan | 2016 |
Therapeutic effect of atropine 1% in children with low myopia.
Topics: Atropine; Child; Disease Progression; Humans; Mydriatics; Myopia; Ophthalmic Solutions | 2016 |
Tropicamide and myopia progression.
Topics: Administration, Topical; Astigmatism; Atropine; Disease Progression; Humans; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Refraction, Ocular; Tropicamide | 2008 |
DFP initiated early alterations of PKA/p-CREB pathway and differential persistence of beta-tubulin subtypes in the CNS of hens contributes to OPIDN.
Topics: Animals; Antidotes; Atropine; Blotting, Northern; Blotting, Western; Central Nervous System; Cerebrum; Chickens; Cholinesterase Inhibitors; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Disease Progression; Female; Immunohistochemistry; Isoflurophate; Neurodegenerative Diseases; Neurotoxicity Syndromes; Phosphorylation; RNA, Messenger; Signal Transduction; Spinal Cord; Time Factors; Tubulin | 2009 |
Atropine treatment for myopia.
Topics: Accommodation, Ocular; Administration, Topical; Atropine; Disease Progression; Double-Blind Method; Humans; Mydriatics; Myopia; Ophthalmic Solutions; Visual Acuity; Withholding Treatment | 2009 |
Prevention of myopia onset with 0.025% atropine in premyopic children.
Topics: Atropine; Child; Cohort Studies; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Photophobia; Refraction, Ocular; Retrospective Studies; Treatment Outcome | 2010 |
Effects of 0.05% racanisodamine on pupil size and accommodation.
Topics: Accommodation, Ocular; Atropine; Child; Disease Progression; Humans; Infrared Rays; Muscarinic Antagonists; Myopia; Ophthalmic Solutions; Photophobia; Pupil; Refraction, Ocular; Solanaceous Alkaloids; Time Factors | 2010 |
An evidence-based update on myopia and interventions to retard its progression.
Topics: Animals; Atropine; Disease Models, Animal; Disease Progression; Female; Humans; Male; Muscarinic Antagonists; Myopia; Orthokeratologic Procedures; Pirenzepine; Prevalence; Risk Factors; Sensory Deprivation | 2011 |
The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren.
Topics: Administration, Ophthalmic; Atropine; Case-Control Studies; Child; Disease Progression; Female; Follow-Up Studies; Humans; Male; Multivariate Analysis; Mydriatics; Myopia; Ophthalmic Solutions; Retrospective Studies | 2011 |
Attempts to reduce the progression of myopia and spectacle prescriptions during childhood: a survey of eye specialists.
Topics: Atropine; Child; Child, Preschool; Data Collection; Disease Progression; Eyeglasses; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Myopia; Practice Patterns, Physicians'; Prescriptions; Republic of Korea | 2011 |
Muscarinic acetylcholine receptor 3 is dominant in myopia progression.
Topics: Adolescent; Adult; Animals; Atropine; Chromosome Mapping; Cricetinae; Disease Models, Animal; Disease Progression; Female; Genetic Predisposition to Disease; Humans; Male; Mesocricetus; Muscarinic Antagonists; Myopia; Receptor, Muscarinic M1; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Receptor, Muscarinic M4; Receptor, Muscarinic M5; Receptors, Muscarinic; Risk Factors; Young Adult | 2012 |
Post-traumatic pseudomyopia.
Topics: Accommodation, Ocular; Adolescent; Adult; Atropine; Craniocerebral Trauma; Diagnostic Techniques, Ophthalmological; Disease Progression; Female; Humans; Male; Myopia; Ocular Motility Disorders; Refraction, Ocular; Visual Acuity | 2003 |
Organophosphorous pesticides in breast cancer progression.
Topics: Adenocarcinoma; Atropine; Breast; Breast Neoplasms; Cell Count; Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; Cholinesterase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Insecticides; Malathion; Parasympatholytics; Parathion; Proliferating Cell Nuclear Antigen; Tumor Suppressor Protein p53 | 2003 |
Interventions to retard myopia progression.
Topics: Atropine; Child, Preschool; Disease Progression; Humans; Infant; Myopia; Parasympatholytics | 2003 |
Prevention of myopia progression with 0.05% atropine solution.
Topics: Atropine; Case-Control Studies; Child; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Retrospective Studies; Taiwan | 2006 |
Muscarinic receptors autoantibodies purified from mammary adenocarcinoma-bearing mice sera stimulate tumor progression.
Topics: Adenocarcinoma; Animals; Atropine; Autoantibodies; Blotting, Western; Carbachol; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Female; Immunoglobulin G; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Muscarinic Antagonists; Neovascularization, Pathologic; Quinuclidinyl Benzilate; Receptors, Muscarinic; Thymidine; Tritium; Vascular Endothelial Growth Factor A | 2006 |
[Preventive surgical treatment of ulcer disease].
Topics: Atropine; Digestive System Surgical Procedures; Disease Progression; Electronic Data Processing; Humans; Muscarinic Antagonists; Peptic Ulcer; Postoperative Complications; Quality of Life; Severity of Illness Index; Stomach; Surveys and Questionnaires; Vagotomy, Proximal Gastric | 2006 |
Progression of myopia.
Topics: Adolescent; Atropine; Child; Disease Progression; Female; Follow-Up Studies; Humans; Male; Minnesota; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular | 1995 |
The effectiveness of 0.5% atropine in controlling high myopia in children.
Topics: Administration, Topical; Adolescent; Analysis of Variance; Atropine; Child; Disease Progression; Female; Humans; Male; Mydriatics; Myopia; Prospective Studies; Tropicamide | 1997 |
Use of dobutamine echocardiography for cardiac risk stratification of patients with chronic renal failure.
Topics: Adrenergic beta-Agonists; Aged; Anti-Arrhythmia Agents; Atropine; Coronary Disease; Death, Sudden, Cardiac; Disease Progression; Disease-Free Survival; Dobutamine; Echocardiography; Female; Humans; Kidney Failure, Chronic; Male; Mass Screening; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Prognosis; Risk | 1998 |
Management of progressive school myopia with topical atropine eyedrops and photochromic bifocal spectacles.
Topics: Adolescent; Atropine; Child; Child, Preschool; Disease Progression; Eyeglasses; Female; Humans; Male; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies; Treatment Outcome | 2000 |
Reducing the progression of myopia with atropine: a long term cohort study of Olmsted County students.
Topics: Adolescent; Atropine; Child; Disease Progression; Female; Follow-Up Studies; Humans; Incidence; Male; Minnesota; Mydriatics; Myopia; Ophthalmic Solutions; Refraction, Ocular; Retrospective Studies | 2000 |
Treatment of childhood myopia with atropine eyedrops and bifocal spectacles.
Topics: Adolescent; Atropine; Child; Disease Progression; Eyeglasses; Female; Humans; Male; Muscarinic Antagonists; Myopia; Patient Compliance; Retrospective Studies; Treatment Outcome | 2001 |
There's no need to risk retinal light toxicity in the medical management of progressive school myopia with atropine (and photochromic bifocals). It is medically indicated.
Topics: Atropine; Child; Disease Progression; Eyeglasses; Humans; Light; Myopia; Parasympatholytics; Pupil; Radiation Injuries; Retina; Risk Factors; Schools | 2001 |